GATIS score for predicting the prognosis of rectal neuroendocrine neoplasms: A Chinese multicenter study of 12-year experience

Table 1 Clinicopathological data of patients with rectal neuroendocrine neoplasms, n (%)

	All (n = 1408)	n
Sex		1408
Female	591 (42.0)
Male	817 (58.0)
Age, year	51.9 (12.1)	1408
Size (cm)		1408
≤ 1	872 (61.9)
1-2	291 (20.7)
> 2	171 (12.1)
NA	74 (5.3)
Size (cm)	1.3 (1.2)	1334
Neoadjuvant therapy		1408
No	1385 (98.4)
Yes	23 (1.6)
Complete resection
No	48 (3.4)
Yes	1360 (96.6)
Pathological type		1408
NET	1307 (92.8)
NEC	71 (5.0)
MANEC	14 (1.0)
NA	16 (1.1)
Pathological grade,		1408
G1	1149 (81.6)
G2	158 (11.2)
G3	85 (6.0)
NA	16 (1.1)
T stage		1408
T1	1150 (81.7)
T2	140 (9.9)
T3	82 (5.8)
T4	36 (2.6)
Lymphatic metastasis		1408
No	1305 (92.7)
Yes	103 (7.3)
TNM stage		1408
I	1133 (80.5)
II	130 (9.2)
III	92 (6.5)
IV	53 (3.8)
Lymph vascular invasion		1408
No	1347 (95.7)
Yes	61 (4.3)
CgA		1408
Negative	1046 (74.3)
Positive	362 (25.7)
Syn		1408
Negative	381 (27.1)
Positive	1027 (72.9)
Adjuvant therapy		1408
No	1318 (93.6)
Yes	90 (6.4)

NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; CgA: Chromogranin A; Syn: Synaptophysin.